Enzymotec has announced that it has received the Israel patent office approval for CardiaBeat® composition and production process. The patent is entitled "Fractionation of phytosterol esters in oil."
The patent (IL 162764) was granted on 08.11.08 following approval from New Zealand and China patent offices.
CardiaBeat® is a lipid-regulating agent, composed of plant sterol esters of Omega-3 fatty acids in an Omega-3 glyceride matrix. CardiaBeat® efficacy in reducing CVD risk factors was evaluated in several clinical trials. The ingredient has additional pending patents around the world and has already gained NDI status in the US, as well as a novel food approval in the European Union.
As part of its strategy, Enzymotec continues to invest efforts in order to strengthen its IP position.
CardiaBeat® has been launched successfully in several countries around the world, including Israel by Teva pharmaceuticals under the brand Phyto-Guard and in India by Elder pharmaceuticals under the brand PhytOmega.
Enzymotec is a developer and manufacturer of innovative, lipid-based biofunctional solutions for orthomolecular medicine, dietary supplements and advanced infant nutrition. Key products are: SharpPS® line of products- phosphatidylserine based ingredients for cognitive improvement, InFat® - structured fat for infant formulas, CardiaBeat® offering a broad health effect to reduce CVD risks and Krill Oil+™.